NCT04275557 Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
| NCT ID | NCT04275557 |
| Status | Recruiting |
| Phase | — |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,174 participants |
| Start Date | 2020-02-18 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,174 participants in total. It began in 2020-02-18 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Florida Pancreas Collaborative wants to partner with individuals who are known to have, or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and are undergoing diagnosis and treatment at a participating institution. The goals of this project are to build a large database of information obtained from blood, tissue, medical images, surveys and information from routine care to develop noninvasive diagnostic approaches that could be used as decision-making tools to effectively personalize clinical care.
Eligibility Criteria
Inclusion Criteria: * Individuals who present to the GI clinic, surgery, or endoscopy at Moffitt, Florida Research Institute (FRI), or UM with a clinical suspicion for (or diagnosis of) a pancreatic lesion, cyst, mass, cancer, or pancreatitis based on symptoms, imaging, or blood-work and has not had any treatment involving their pancreas. * Able to understand and voluntarily sign the informed consent. * Willing to complete study questionnaire(s) and donate medical images and/or biological specimens (including blood, cystic fluid, and/or tissue) obtained at the time of standard of care procedures (biopsy, surgery, and venipuncture) after signing the informed consent document Exclusion Criteria: * No suspicion or diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis. * Has a diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis and has already undergone treatment involving the pancreas (which may involve surgery, chemo- or immuno-therapy, and/or radiation). * Unable to provide informed consent. * Unwilling to complete study questionnaire(s) and/or donate biological specimens or images.
Contact & Investigator
Jennifer Permuth, PhD
PRINCIPAL INVESTIGATOR
Moffitt Cancer Center
Frequently Asked Questions
Who can join the NCT04275557 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04275557 currently recruiting?
Yes, NCT04275557 is actively recruiting participants. Contact the research team at Toni.Basinski@moffitt.org for enrollment information.
Where is the NCT04275557 trial being conducted?
This trial is being conducted at Lakewood Rch, United States, Miami, United States, Tampa, United States.
Who is sponsoring the NCT04275557 clinical trial?
NCT04275557 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Jennifer Permuth, PhD at Moffitt Cancer Center. The trial plans to enroll 1,174 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.